Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.

The Journal of clinical investigation ·Vol. 105 ·No. 1 ·2000-01-00 ·Pages 3-7

Druker BJ, Lydon NB

Abstract

暂无摘要

MeSH Terms

Antineoplastic Agents/therapeutic use Benzamides Binding Sites Drug Design Enzyme Inhibitors/therapeutic use Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy Piperazines/pharmacology,therapeutic use Protein-Tyrosine Kinases/antagonists & inhibitors Proto-Oncogene Proteins c-abl/antagonists & inhibitors,chemistry Pyrimidines/pharmacology,therapeutic use

Chemicals

Antineoplastic Agents Benzamides Enzyme Inhibitors Piperazines Pyrimidines Imatinib Mesylate Protein-Tyrosine Kinases Proto-Oncogene Proteins c-abl

Authors & Affiliations

2 authors, click to expand affiliations / ORCID

Druker B J

Division of Hematology, Oregon Health Sciences University, Portland, Oregon 97201, USA.

Lydon N B

References (27)

27 references, click to expand

Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Clin Cancer Res. 1998 Jul;4(7):1661-72 PMID: 9676840
Protein tyrosine kinases and cancer.
Biochim Biophys Acta. 1997 Dec 9;1333(3):F217-48 PMID: 9426205
Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor.
Mol Cell. 1999 May;3(5):639-48 PMID: 10360180
Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors.
Structure. 1999 Jun 15;7(6):651-61 PMID: 10404594
The structure-based design of ATP-site directed protein kinase inhibitors.
Curr Med Chem. 1999 Sep;6(9):775-805 PMID: 10495352
Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.
Nature. 1973 Jun 1;243(5405):290-3 PMID: 4126434
Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia.
Nature. 1983 Nov 17-23;306(5940):239-42 PMID: 6316147
Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia.
Nature. 1983 Nov 17-23;306(5940):277-80 PMID: 6580527
An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.
Cell. 1984 Jul;37(3):1035-42 PMID: 6204766
Fused transcript of abl and bcr genes in chronic myelogenous leukaemia.
Nature. 1985 Jun 13-19;315(6020):550-4 PMID: 2989692
The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene.
Science. 1986 Jul 11;233(4760):212-4 PMID: 3460176
Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia.
Cell. 1987 Oct 9;51(1):33-40 PMID: 2820585
Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL).
Science. 1988 Feb 12;239(4841 Pt 1):775-7 PMID: 3422516
The molecular genetics of Philadelphia chromosome-positive leukemias.
N Engl J Med. 1988 Oct 13;319(15):990-8 PMID: 3047582
The viral and cellular forms of the Abelson (abl) oncogene.
Adv Virus Res. 1988;35:39-81 PMID: 2852893
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
Science. 1990 Feb 16;247(4944):824-30 PMID: 2406902
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
Science. 1990 Mar 2;247(4946):1079-82 PMID: 2408149
Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.
Proc Natl Acad Sci U S A. 1990 Sep;87(17):6649-53 PMID: 2204061
Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia.
J Biol Chem. 1994 Sep 16;269(37):22925-8 PMID: 8083188
Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2558-62 PMID: 7708684
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
Cancer Res. 1996 Jan 1;56(1):100-4 PMID: 8548747
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.
Nat Med. 1996 May;2(5):561-6 PMID: 8616716
Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC).
Arch Pharm (Weinheim). 1996 Jul;329(7):371-6 PMID: 8764886
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.
Blood. 1997 Nov 1;90(9):3691-8 PMID: 9345054
Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
J Med Chem. 1997 Oct 24;40(22):3601-16 PMID: 9357527
CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins.
Blood. 1997 Dec 15;90(12):4947-52 PMID: 9389713
In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.
J Natl Cancer Inst. 1999 Jan 20;91(2):163-8 PMID: 9923858

Article Info

Journal

The Journal of clinical investigation

Abbr.

J Clin Invest

ISSN

0021-9738

DOI

10.1172/JCI9083

Published

2000-01-00

Pages

3-7

Language

English

Region

United States

NLM ID

7802877

PMCID

PMC382593

Subset

External Links

PubMed source DOI: 10.1172/JCI9083 PMC Full Text View journal details

Analysis Services

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.

Contact

WeChat Official Account